OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).
Attempting dual immunotherapy after checkpoint failure worsened outcomes, redirecting research toward more effective salvage strategies for advanced throat cancer.
OPTIM, a randomized phase II trial in platinum-refractory R/M-SCCHN, compared staggered nivolumab to nivolumab+ipilimumab against docetaxel at PD-1 progression; NIVO-IPI showed 0% objective response vs 17.6% for docetaxel and numerically worse OS (3.97 vs 11.9 months). This clinically important negative result closes the staggered dual-checkpoint hypothesis and redirects research away from sequential checkpoint intensification as a salvage strategy after PD-1 failure in SCCHN.
What the study was
- Study design
- randomized_phase2_trial
- Population
- Patients with recurrent/metastatic SCCHN refractory to anti-PD-1 therapy
- Sample size
- 31
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Br J Cancer
Why it surfaced
Critical phase II RCT negative result for a major clinical question in SCCHN - definitively shows staggered checkpoint inhibition fails after anti-PD-1 progression; guides clinical decision-making and shapes future trial design in this high-unmet-need, post-immunotherapy setting.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.